Abstract
Background
In India, about half of the total health expenditure is spent on medicines. The projected increase in various diseases coupled with the skyrocketing drug prices have further compounded the drug cost burden. We conducted a study to assess the awareness, attitudes, and practices of physicians with regard to various cost containment measures and the factors affecting them.
Methods
A cross-sectional, questionnaire-based, observational study was conducted over a period of 3 months among 200 physicians, after permission from the Institutional Ethics Committee, at the Grant Medical College and Sir J J Group of Hospitals, Mumbai. The STROBE (Strengthening The Reporting of OBservational studies in Epidemiology) guidelines were followed.
Results
Cost considerations were important to 97 % of government doctors (GDs) and 72 % of private doctors (PDs). Eighty percent of both GDs and PDs said that safety and efficacy were more important than cost. Seventy-one percent of GDs and 65 % of PDs knew about the various cost reduction methods. Twenty-four percent of GDs and 65 % of PDs said that they graded drugs according to cost. Ninety-four percent of GDs and 73 % of PDs said that patent protection should not be extended to life-saving drugs. Sixty-four percent of GDs and 10 % of PDs, and 20 % of GDs and 10 % of PDs were in favor of the stepwise introduction of drugs and the use of generics, respectively. Factors precluding the use of cheaper alternatives were narrow therapeutic index drugs (43.5 %) and fear of substandard quality (38.5 %).
Conclusion
Doctors are indeed concerned about the high cost of drugs. More awareness needs to be created about the use of cheaper generics. The government has a very important role to play in reducing the cost of prescription drugs and making healthcare affordable.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
National Pharmaceuticals Pricing Policy, 2011 [Internet]. 2011. http://pharmaceuticals.gov.in/mshT2810/FTY2.pdf.
Gill J, Taylor D. Health and healthcare in India: national opportunities and global impact [Internet]. 2013. http://www.ucl.ac.uk/pharmacy/documents/news_docs/healthcareinindiajuly2013.
PricewaterhouseCoopers. Healthcare in India: emerging market report 2007 [Internet]. 2007. http://www.pwc.com/en_GX/gx/healthcare/pdf/emerging-market-report-hc-in-india.pdf.
National Commission on Macroeconomics and Health Ministry of Health & Family Welfare, Government of India. Report of the National Commission on Macroeconomics and Health [Internet]. New Delhi; 2005. http://www.who.int/macrohealth/action/Report of the National Commission.pdf.
Eaddy MT, Cook CL, O’Day K, et al. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T [Internet]. 2012 (cited 2013 Oct 15); 37(1):45–55. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3278192&tool=pmcentrez&rendertype=abstract.
Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. [Internet]. 2005 (cited 2013 Oct 15); 1(3):189–99. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1661624&tool=pmcentrez&rendertype=abstract.
Suggs LS, Raina P, Gafni A, et al. Family physician attitudes about prescribing using a drug formulary. BMC Fam Pract. [Internet]. 2009 (cited 2013 Jul 20); 10:69. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2770461&tool=pmcentrez&rendertype=abstract.
Shamima K, Robert S, David S, Bruce P. Physicians’ opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern States. JMCP [Internet]. 2008; 14(8):780–9. http://www.amcp.org/data/jmcp/Oct08-all.pdf.
Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. Hill S, editor. PLoS Med. [Internet]. Public Library of Science; 2007 (cited 2013 May 31); 4(9):e283. doi:10.1371/journal.pmed.0040283.
Von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ [Internet]. 2007;335(7624):806–8. Available from: http://www.emgo.nl/kc/Analysis/statements/observationalstudies-lancet-2007.pdf.
Shrank WH, Young HN, Ettner SL, et al. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care [Internet]. 2005 (cited 2013 Jul 19); 11(1):16–22. http://www.ncbi.nlm.nih.gov/pubmed/15697096.
Banahan BF, Kolassa E. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157:2080–8.
Dean A, Sullivan K, Soe M. OpenEpi: open source epidemiologic statistics for public health, version 2.3.1 [Internet]. 2011 (cited 2012 Oct 10). http://www.OpenEpi.com.
Urbanski P, Wolf A, Herman WH. Cost-effectiveness issues of diabetes prevention and treatment [Internet]. 2007. https://dpg-storage.s3.amazonaws.com/dce/resources/cost_effective.pdf.
Eaddy MT, Shah M, Lunacsek O, Stanford RH. The burden of illness of hypertension and comorbid diabetes. Curr Med Res Opin [Internet]. 2008 (cited 2013 Jul 20); 24(9):2501–7. http://www.ncbi.nlm.nih.gov/pubmed/18671895.
Anand K, Pandav CS, Nath LM. Impact of HIV/AIDS on the national economy of India. Health Policy [Internet]. 1999 (cited 2013 Jul 20);47(3):195–205. http://www.ncbi.nlm.nih.gov/pubmed/10538918.
Sharma EK. Killer costs. Bus. Today [Internet]. 2013. http://businesstoday.intoday.in/story/cancer-treatment-cost/1/191785.html.
Kannan R. Cancer care can burn a big hole in pocket. The Hindu [Internet]. 2012. http://www.thehindu.com/sci-tech/health/policy-and-issues/cancer-care-can-burn-a-big-hole-in-pocket/article2866649.ece.
Laurance J. The real cancer killer: rip-off prices for drugs set by “profiteering” Big Pharma giants. Indep. [Internet]. 2013. http://www.independent.co.uk/news/uk/home-news/the-real-cancer-killer-ripoff-prices-for-drugs-set-by-profiteering-big-pharma-giants-8591825.html.
Srivastava R. National policy for containment of antimicrobial resistance, India. [Internet]. 2011. http://www.ncdc.gov.in/ab_policy.pdf.
Marsh Inc. The economic and social impact of emerging infectious disease: mitigation through detection, research, and response [Internet]. 2008. http://www.healthcare.philips.com/main/shared/assets/documents/bioshield/ecoandsocialimpactofemerginginfectiousdisease_111208.pdf.
Jamshed SQ, Hassali MAA, Ibrahim MIM, Babar Z-D. Knowledge attitude and perception of dispensing doctors regarding generic medicines in Karachi, Pakistan: a qualitative study. J Pak Med Assoc [Internet]. 2011 (cited 2013 Jul 20); 61(1):80–3. http://www.ncbi.nlm.nih.gov/pubmed/22368910.
Banahan BF. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med [Internet]. American Medical Association; 1997 (cited 2013 Jul 19); 157(18):2080. http://archinte.jamanetwork.com/article.aspx?articleid=623881.
American Society of Health-System Pharmacists. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health Pharm [Internet]. 2008; 65:1368–84. http://www.ashp.org/DocLibrary/BestPractices/MgmtGdlCostManag.aspx.
Karki SD, Chandra P, Holden JMC, Shehata H. Impact of team approach on reducing drug costs. Int J Geriatr Psychiatry [Internet]. 1988 (cited 2013 Jul 20); 3(2):89–93. doi:10.1002/gps.930030204.
Rawlins MD. Cutting the cost of drug development? Nat Rev Drug Discov [Internet]. 2004;3:360–4. http://archives.who.int/prioritymeds/report/append/barr_apx4B.pdf.
Stafford RS, Radley DC. The potential of pill splitting to achieve cost savings. AJMC [Internet]. 2002; 8(8):706–12. http://www.ajmc.com/publications/issue/2002/2002-08-vol8-n8/Aug02-152p706-712/.
Cross M. Two for the price of one: beauty of pill-splitting catches on [Internet]. Manag Care. 2003. http://www.managedcaremag.com/archives/0302/0302.pillsplitting.html.
Meadows M. Saving money on prescription drugs [Internet]. U.S. Food Drug Adm. 2005 (cited 2013 Jan 10). http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm134215.htm.
Shrank W, Liberman J, Fischer M, Girdish C, Brennan T, Choudhry N. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45:31–8.
Gordon SM. Antibiotic prophylaxis against postoperative wound infections. Cleve Clin J Med [Internet]. 2006 (cited 2013 Jul 20); 73(Suppl_1):S42–45. http://www.ccjm.org/content/73/Suppl_1/S42.abstract.
Burke JP. Maximizing appropriate antibiotic prophylaxis for surgical patients: an update from LDS Hospital, Salt Lake City. Clin Infect Dis [Internet]. 2001 (cited 2013 Jul 20); 33(Supplement_2):S78–83. http://cid.oxfordjournals.org/content/33/Supplement_2/S78.full.
Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA [Internet]. 2004 (cited 2013 Jul 20); 291(15):1850–6. http://www.ncbi.nlm.nih.gov/pubmed/15100203.
Caudill TS, Mitzi SJ, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996;5:201–6.
Shrank WH, Liberman JN, Fischer MA, et al. Physician perceptions about generic drugs. Ann Pharmacother [Internet]. 2011 (cited 2013 Jun 16); 45(1):31–8. http://www.theannals.com/content/45/1/31.abstract.
National Pharmaceutical Pricing Policy [Internet]. Natl. Pharm. Pricing Authority, Gov. India. 2012 (cited 2013 Apr 12). http://www.nppaindia.nic.in/index1.html.
What is Jan Aushadi? [Internet]. Dep. Pharm. Gov. India. http://janaushadhi.gov.in/.
Alexander J. Parliamentary panel raps DoP for going slow on Jan Aushadhi Programme [Internet]. PharmaBiz. 2012. http://pharmabiz.com/NewsDetails.aspx?aid=69040&sid=1.
Jayaraman K. Troubles beset “Jan Aushadhi” plan to broaden access to generics. Nat Med [Internet]. Nature Publishing Group; 2010 (cited 2013 Jul 20); 16(4):350. doi:10.1038/nm0410-350a.
Department of Pharmaceuticals. Drugs Prices Control Order 2013 [Internet]. 2013. http://pharmaceuticals.gov.in/DPCO2013.pdf.
Govt. of India. India - Macro-economic Summary: 1999–2000 to 2012–13 (E) [Internet]. Plan. Comm.-Gov. India. 2013. http://planningcommission.gov.in/data/datatable/2504/databook_1.pdf.
Ministry of Labour & Employment. Rashtriya Swasthya Bima Yojana (RSBY)-Highlights [Internet]. Press Inf. Bur. Gov. India. 2013. http://www.pib.nic.in/newsite/erelease.aspx?relid=94269.
Dhoot V. Rashtriya Swasthya Bima Yojana: UPA’s flagship, opposition’s pride. Econ. Times [Internet]. 2011. http://articles.economictimes.indiatimes.com/2011-03-19/news/29146333_1_upa-flagship-poverty-schemes-rsby.
Dhoot V. Efficacy of government health cover scheme Rashtriya Swasthya Bima Yojana under scanner. Econ Times [Internet]. 2013. http://articles.economictimes.indiatimes.com/2013-10-08/news/42829102_1_rashtriya-swasthya-bima-yojana-rsby-domestic-workers.
Sinha S. Govt-sponsored schemes: Meant for poor, but beyond their reach. Econ Times [Internet]. 2012. http://articles.economictimes.indiatimes.com/2012-08-29/news/33476145_1_insurance-scheme-rsby-rashtriya-swasthya-bima-yojana.
Williams E. Remembering the public’s interest in the patent system: a post-grant opposition designed to benefit the public [Internet]. 2006. http://bciptf.org/wp-content/uploads/2011/07/27-EricWilliamsIPTF2006.pdf.
Thomas JR. HIV/AIDS drugs, patents and the TRIPS agreement: issues and options [Internet]. Congr Res Serv Libr Congr. 2001. http://www.law.umaryland.edu/marshall/crsreports/crsdocuments/RL31066.pdf.
Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: development trends and strategies. J Pharm Bioallied Sci [Internet]. 2010 (cited 2013 Jul 20); 2(4):290–9. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2996062&tool=pmcentrez&rendertype=abstract.
World Trade Organisation. Agreement on trade-related aspects of intellectual property rights [Internet]. 1994. http://www.wto.org/english/res_e/booksp_e/analytic_index_e/trips_e.htm.
Essential Medicines and Health Products Information Portal. Implications of the Doha Declaration on the trips agreement and public health: health economics and drugs series no. 012 [Internet]. World Health Organization; 2002. http://apps.who.int/medicinedocs/en/d/Js2301e/9.html.
World Trade Organisation. The separate Doha Declaration explained [Internet]. 2001. http://www.wto.org/english/tratop_e/trips_e/healthdeclexpln_e.htm.
Musungu SF, Villanueva S, Blasetti R. Utilizing TRIPS flexibilities for public health protection through south-south regional frameworks [Internet]. Geneva: World Health Organization; 2004. p. 12. http://apps.who.int/medicinedocs/pdf/s4968e/s4968e.pdf.
Haddad WF. Compulsory licensing of life-saving medicines [Internet]. 2013. http://www.equilibri.net/nuovo/es/node/2462.
Novartis: India rejects patent plea for cancer drug Glivec [Internet]. BBC News-Bus. 2013 (cited 2013 Dec 1). http://www.bbc.co.uk/news/business-21991179.
LaMattina J. India’s solution to costly drugs: ignore patents and control prices: except for home grown drugs [Internet]. Pharma Helathcare—Forbes. 2013 (cited 2013 Dec 1). http://www.forbes.com/sites/johnlamattina/2013/04/08/indias-solution-to-drug-costs-ignore-patents-and-control-prices-except-for-home-grown-drugs/.
Maharashtra Food and Drug Administration. Raids conducted by FDA Maharashtra [Internet]. Mumbai; 2008. http://www.fda-mah.com/Raid.doc.
Sinha K. Maharahstra, TN account for 36 % of sub-standard drugs. The Times of India [Internet]. New Delhi; 2012. http://articles.timesofindia.indiatimes.com/2012-08-22/india/33321447_1_spurious-drugs-shortage-of-drug-inspectors-pharmaceutical-trade-interests.
Mahalakshmi B, Raghavan S. Barring the way of fake drugs. Financ Express [Internet]. 2013. http://www.financialexpress.com/news/barring-the-way-of-fake-drugs/1072254/3.
Nautiyal S. Maharashtra FDA to implement billing inspections stringently. PharmaBiz [Internet]. Mumbai; 2013. http://www.pharmabiz.com/NewsDetails.aspx?aid=76375&sid=1.
Gupta RK, Reddy PS. A calm look on cost analysis of different brands of anti-epileptic drugs. J MGIMS [Internet]. 2011;16(1):64–6. http://medind.nic.in/jaw/t11/i1/jawt11i1p64.pdf.
Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy [Internet]. (cited 2013 Jul 20); 15(4):433–40. http://www.ncbi.nlm.nih.gov/pubmed/7479195.
Pope N. Generic substitution of narrow therapeutic index drugs. US Pharm [Internet]. 2009;34(6):12–9. http://www.uspharmacist.com/content/s/78/c/13854/.
Conflicting Interest
None.
Author Contributions
Gauri Billa: Topic selection and conceptualization; substantial contributions to conception and design; acquisition of data, revising the article critically for important intellectual content; final approval of the version to be published.
Karan Thakkar: Corresponding author and guarantor, designing the data collection tool, acquisition of data, analysis and interpretation of data; drafting the article and revising it critically for important intellectual content; proof reading; final approval of the version to be published.
Sarita Jaiswar: Acquisition of data, analysis and interpretation of data; drafting the article and revising it critically for important intellectual content; proof reading; final approval of the version to be published.
Dinesh Dhodi: Data analysis, revising the article critically for important intellectual content; final approval of the version to be published.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Rights and permissions
About this article
Cite this article
Billa, G., Thakkar, K., Jaiswar, S. et al. A Cross-Sectional Study to Evaluate the Awareness and Attitudes of Physicians Towards Reducing the Cost of Prescription Drugs, Mumbai. Appl Health Econ Health Policy 12, 125–137 (2014). https://doi.org/10.1007/s40258-014-0080-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40258-014-0080-2